
Opinion|Videos|December 17, 2024
Key Insights on the Use of Inhaled Treprostinil in Treating CTD-PAH
Author(s)Steven D. Nathan, MD
Key Takeaways
- Development of therapies that halt or reverse IPF and PAH progression is a significant unmet need.
- Improved diagnostic tools are essential for earlier detection and intervention in IPF and PAH.
Steven Nathan, MD, discusses how the study on inhaled treprostinil for CTD-PAH demonstrates its comparable efficacy to intravenous and subcutaneous forms, with a better safety profile, which could lead to improved patient adherence and management of CTD-PAH.
Advertisement
Episodes in this series

- Briefly describe the abstract “Inhaled Treprostinil for the Treatment of Connective Tissue-Associated Pulmonary Arterial Hypertension.”
- What was the objective of this study?
- How was this study designed/what methodology was used?
- What results were presented?
- What are your key takeaways from this study, and what are the clinical implications in utilizing inhaled treprostinil compared with intravenous or subcutaneous treprostinil for connective tissue disease-associated PAH?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Nerandomilast for Idiopathic Pulmonary Fibrosis
2
Pulling Back Funding for Research Could Leave HIV Treatment in Worse State: Patrick Sullivan, DVM, PhD
3
Value-Based Care Interventions and Management of CKD Progression
4
FDA Approves Cemiplimab as First, Only Adjuvant Immunotherapy for High-Risk CSCC
5